If a patient still has markedly elevated inflammatory markers on day 14 of Zerbaxa (ceftazidime‑avibactam) therapy, should the antibiotic be continued?

Should Zerbaxa Be Continued if Inflammatory Markers Remain Elevated on Day 14?

If a patient still has markedly elevated inflammatory markers on day 14 of Zerbaxa therapy, you should NOT automatically continue the antibiotic—instead, perform a comprehensive reassessment to identify the underlying cause, as persistent inflammation at this timepoint suggests either treatment failure, a non-bacterial source, or an undrained focus requiring intervention.

Clinical Decision Framework

Immediate Actions Required

Reassess for the source of persistent inflammation:

• Repeat imaging (CT chest/abdomen) to identify abscesses, undrained collections, or fungal infections 1
• Review all culture results and obtain new cultures from blood and suspected infection sites 2
• Examine for catheter-related infections or other avascular sites 2
• Consider non-infectious causes: drug fever, venous thrombosis, pulmonary embolism 3

Key Decision Points Based on Clinical Stability

If the patient is clinically stable (no deterioration, vital signs improving despite elevated markers):

• Continue current antibacterial therapy while completing the diagnostic workup 1
• Some bacterial infections require 5+ days before defervescence occurs even with appropriate therapy 2

If the patient is clinically unstable or deteriorating:

• Seek urgent consultation from infectious disease specialist or clinical microbiologist 1
• Consider broadening coverage or rotating antibacterial therapy 1
• Add empiric antifungal therapy if fever/inflammation persists beyond 4-6 days, particularly with rising CRP 1

Duration of Therapy Guidance

According to FDA labeling, Zerbaxa treatment duration varies by indication 4:

• Complicated intra-abdominal infections: 4-14 days
• Complicated urinary tract infections: 7 days
• Hospital-acquired/ventilator-associated pneumonia: 8-14 days

Critical consideration: The median time to clinical response for febrile neutropenic patients is 5-7 days, with some requiring up to 7 days for defervescence 2. By day 14, persistent inflammation warrants investigation rather than automatic continuation.

Specific Scenarios to Address

If Rising CRP Without Fever

Proceed immediately to imaging (chest and upper abdomen) to exclude fungal infection, yeast infection, or abscesses 1. Initiate antifungal therapy if imaging suggests fungal etiology 1.

If Pathogen Identified

Continue appropriate specific therapy based on susceptibility results 1. However, if the organism is susceptible to Zerbaxa and inflammation persists at day 14, suspect:

• Inadequate source control (undrained abscess)
• Superinfection with resistant organism or fungus
• Development of resistance during therapy (documented risk with ceftazidime-avibactam) 5

If No Pathogen Identified

This scenario is particularly challenging. Consider:

• Stopping antibiotics if reassessment reveals no evidence of ongoing infection and the patient is otherwise improving 6
• The risk of continued unnecessary antimicrobial therapy includes selection of resistant pathogens and drug-related adverse effects 6

Common Pitfalls to Avoid

1. Do not reflexively continue antibiotics based solely on elevated inflammatory markers without clinical correlation—CRP and other markers can remain elevated from non-infectious causes 7

2. Do not ignore the possibility of fungal superinfection—this is the most common cause of persistent inflammation beyond 4-6 days in high-risk patients 1

3. Do not overlook source control issues—antibiotics alone cannot cure undrained abscesses or infected foreign bodies 3

4. Monitor for renal function changes—Zerbaxa requires dose adjustment for renal impairment, and combination therapy (particularly with colistin) increases nephrotoxicity risk 4, 8

Evidence Considerations

The available guidelines primarily address febrile neutropenia and general sepsis management [1-9,6], not specifically Zerbaxa duration decisions. Recent research shows that ceftazidime-avibactam (similar agent) demonstrates clinical cure rates of 54-70% by day 14 10, 11, suggesting that persistent inflammation at this timepoint represents treatment failure requiring intervention rather than simple continuation.

The Surviving Sepsis Campaign emphasizes that antimicrobial decisions must be based on clinician judgment and clinical information, with thoughtful de-escalation even when cultures are negative if adequate clinical improvement has occurred 6.